Celldex Therapeutics, Inc. — Director's Dealing 2009

Oct 6, 2009

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2009-10-01

Reporting Person: SHANNON TIMOTHY M (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, par value $.001 per share	66212	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to purchase)	$2.48	2019-01-20	Common Stock, par value $.001 per share (155986)		Direct
Stock Option (right to purchase)	$4.89	2017-09-25	Common Stock, par value $.001 per share (68475)		Direct
Stock Option (right to purchase)	$4.89	2017-09-25	Common Stock, par value $.001 per share (68475)		Direct

Footnotes

F1: Received in exchange for 241,740 shares of CuraGen, Corp. ("CuraGen") common stock, at an exchange ratio of .2739, in connection with the merger of CuraGen with and into Cottrell Merger Sub, Inc., a direct wholly-owned subsidiary of Celldex Therapeutics, Inc. (the "Merger").

F2: Received in the Merger in exchange for a stock option to acquire 569,500 shares of CuraGen common stock for $.68 per share.

F3: Received in the Merger in exchange for a stock option to acquire 250,000 shares of CuraGen common stock for $1.34 per share.

F4: Received in the Merger in exchange for a stock option to acquire 250,000 shares of CuraGen common stock for $1.34 per share